The cost of failed first-line cancer treatment related to continued smoking in Canada.
Attributable cancer treatment failures
cost burden
smoking cessation
Journal
Current oncology (Toronto, Ont.)
ISSN: 1718-7729
Titre abrégé: Curr Oncol
Pays: Switzerland
ID NLM: 9502503
Informations de publication
Date de publication:
12 2020
12 2020
Historique:
entrez:
31
12
2020
pubmed:
1
1
2021
medline:
25
9
2021
Statut:
ppublish
Résumé
Smoking by cancer patients and survivors causes adverse cancer treatment outcomes, but little information is available about how smoking can affect cancer treatment costs. We developed a model to estimate attributable cancer treatment failure because of continued smoking after a cancer diagnosis (af Of 206,000 patients diagnosed with cancer annually, an estimated 4789 experienced af The costs associated with af
Sections du résumé
Background
Smoking by cancer patients and survivors causes adverse cancer treatment outcomes, but little information is available about how smoking can affect cancer treatment costs.
Methods
We developed a model to estimate attributable cancer treatment failure because of continued smoking after a cancer diagnosis (af
Results
Of 206,000 patients diagnosed with cancer annually, an estimated 4789 experienced af
Conclusions
The costs associated with af
Identifiants
pubmed: 33380862
doi: 10.3747/co.27.5951
pii: conc-27-307
pmc: PMC7755446
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
307-312Informations de copyright
2020 Multimed Inc.
Déclaration de conflit d'intérêts
CONFLICT OF INTEREST DISCLOSURES We have read and understood Current Oncology’s policy on disclosing conflicts of interest, and we declare that we have none.
Références
Clin Cancer Res. 2019 May 1;25(9):2691-2698
pubmed: 30642913
Pract Radiat Oncol. 2016 Jan-Feb;6(1):12-8
pubmed: 26598909
Cancer Causes Control. 2013 Jun;24(6):1223-30
pubmed: 23553611
Eur Urol. 2017 Nov;72(5):712-735
pubmed: 28366513
Cancer. 2012 Jun 15;118(12):3153-64
pubmed: 22271645
JAMA Oncol. 2015 Sep;1(6):807-13
pubmed: 26226181
Cancer. 2014 Jul 1;120(13):1914-6
pubmed: 24687615
Transl Lung Cancer Res. 2019 May;8(Suppl 1):S11-S20
pubmed: 31211102
Cancer. 2011 Nov 1;117(21):4948-57
pubmed: 21495019
Lung Cancer. 2010 Feb;67(2):221-6
pubmed: 19497635
J Natl Compr Canc Netw. 2016 Nov;14(11):1430-1468
pubmed: 27799513
J Thorac Oncol. 2011 Dec;6(12):2097-103
pubmed: 22052223
Lancet. 2016 Apr 9;387(10027):1540-1550
pubmed: 26712084
Healthc Policy. 2017 Feb;12(3):95-108
pubmed: 28277207
Eur Arch Otorhinolaryngol. 2014 Jan;271(1):125-32
pubmed: 23797970
Breast Cancer Res. 2014 Apr 19;16(2):R42
pubmed: 24745601
Lung Cancer. 2005 Mar;47(3):351-9
pubmed: 15713518
J Med Econ. 2016;19(2):135-47
pubmed: 26442575
CMAJ Open. 2018 Jan 4;6(1):E1-E10
pubmed: 29301745
Palliat Med. 2015 Dec;29(10):918-28
pubmed: 26330452
Curr Oncol. 2016 Jun;23(3):201-3
pubmed: 27330349
Radiother Oncol. 2012 Apr;103(1):45-8
pubmed: 22119370
JAMA Netw Open. 2019 Apr 5;2(4):e191703
pubmed: 30951159
Cancer Epidemiol Biomarkers Prev. 2013 Dec;22(12):2404-11
pubmed: 24319070
Eur Respir J. 2009 Apr;33(4):915-30
pubmed: 19336594
Dis Colon Rectum. 2008 Aug;51(8):1195-201
pubmed: 18523823
Cancer Med. 2018 Sep;7(9):4765-4772
pubmed: 30019421
J Thorac Oncol. 2015 Jul;10(7):1014-9
pubmed: 26102442
Transl Lung Cancer Res. 2019 May;8(Suppl 1):S59-S66
pubmed: 31211106
Immunotherapy. 2019 Dec;11(17):1463-1478
pubmed: 31738117
Eur Urol. 2015 Dec;68(6):949-56
pubmed: 26050111